<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094444</url>
  </required_header>
  <id_info>
    <org_study_id>09.15</org_study_id>
    <nct_id>NCT01094444</nct_id>
  </id_info>
  <brief_title>Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis</brief_title>
  <official_title>Placebo-controlled Trial Investigating the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore the benefit of topical vitamin K3 lotion for the&#xD;
      reactivation/rephosphorylation of EGF-receptor in the skin and the possible reduction in&#xD;
      cutaneous side effects of EGFr-inhibition.&#xD;
&#xD;
      Primary aim: The possible reduction of cutaneous side effects: folliculitis, dryness and&#xD;
      redness of the skin.&#xD;
&#xD;
      Secondary aim: To explore any possible side effects of topical vitamin K3 lotion.&#xD;
&#xD;
      Methods: 36 patients with metastatic colorectal cancer or metastatic head and neck cancer&#xD;
      allocated to treatment with chemotherapy and biweekly cetuximab. Two equally sized areas of&#xD;
      at least 10x10 cm on the back or chest of the patient is marked. Patients receive in a double&#xD;
      blinded procedure placebo lotion on one side and vitamin K3 lotion on the other side. The&#xD;
      treatment may last for a maximum of two months and the patients are followed biweekly with&#xD;
      photos, VAS-scores, questionnaires and CTCAE estimations. The patient will be able to take&#xD;
      weekly photos at home during the weeks they are not seen at the outpatient clinic. During the&#xD;
      treatment all other skin products or antibiotics is allowed and will be carefully registered&#xD;
      by the health care professionals in the outpatient clinic.&#xD;
&#xD;
      The patient may enter the trial in two different ways: 18 patients start treatment with study&#xD;
      lotions at the time they start treatment with cetuximab. The other 18 patients start&#xD;
      treatment with study lotions when folliculitis appears.&#xD;
&#xD;
      Patients are asked for 1.5 mm skin biopsies of both study areas of the skin before start of&#xD;
      treatment and after 4 weeks of treatment with placebo lotion and vitamin K3 lotion. These&#xD;
      biopsies will be investigated for EGFr, phosphorylated EGFr and other central downstream&#xD;
      mechanisms. The biopsy part of the study is optional for the patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Potential reduction in skin toxicity by vitamin K3 lotion</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction in numbers of papulo-pustular eruptions in the treatment fields. Changes in follicular eruptions, dryness/redness of skin estimated by CTCAE 4.0. Patients own experience of efficacy estimated by questionaire and VAS scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential toxicity of vitamin K3 lotion</measure>
    <time_frame>3 months</time_frame>
    <description>No systemic or skin toxicity is expected. Therefore all experienced skin changes will be estimated by CTCAE 4.0. Furthermore, broad bloodtest screenings will be done bi-weekly.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Folliculitis</condition>
  <arm_group>
    <arm_group_label>Vitamin K3-lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A lotion containing 1.5 mM Vitamin K3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard lotion without Vitamin K3</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vitamin K3</intervention_name>
    <description>Lotion containing 1.5 mM Vitamin K3</description>
    <arm_group_label>Vitamin K3-lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned or ongoing treatment with cetuximab&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Informed written consent according to local and national legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known disease that can influence either treatment, evaluation and the outcome of the&#xD;
             current disease and treatment, including chronic dermatology&#xD;
&#xD;
          -  Known hypersensitivity to menadion&#xD;
&#xD;
          -  Concomitant treatment with Vitamin K or Vitamin K-antagonists&#xD;
&#xD;
          -  Known psychological, family, sociological or geographic conditions which potentially&#xD;
             can influence planned study treatment or follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper G. Eriksen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Eriksen JG, Kaalund I, Clemmensen O, Overgaard J, Pfeiffer P. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash. Support Care Cancer. 2017 Jul;25(7):2179-2185. doi: 10.1007/s00520-017-3623-x. Epub 2017 Feb 15.</citation>
    <PMID>28197850</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin K3 lotion</keyword>
  <keyword>Cetuximab induced folliculitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folliculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

